论文部分内容阅读
用生化定性检测方法对451例各种恶性肿瘤患者,46例非癌病人及42例健康人晨尿对羟苯丙酮酸(HPPA)进行测定,结果显示各种恶性肿瘤病人检测的阳性率均明显高于健康对照组及非癌疾病组(P<0.005),对恶性肿瘤的总阳性率为67.85%,特异性为85.23%。对手术、放疗或化疗前后尿中HPPA检测发现,经有效的治疗尤其是手术后,尿中HPPA检测的阳性率明显减低,与治疗前相比有非常显著性差异(P<0.005)。同时,对肿瘤进展、复发及转移患者尿中HPPA检测发现,其阳性申明显高于缓解期、无复发及转移的病人,经统计分析亦有显著性差异(P<0.05~0.005)。所以,检测尿中HPPA不但可作为肿瘤代谢异常的标志物用于肿瘤普查和自查,也可作为病情监测,疗效判定,监测复发或评估预后的一个指标。
The urinary hydroxyphenylpyruvate (HPPA) was detected in 451 patients with various malignant tumors, 46 non-cancer patients and 42 healthy persons by biochemical qualitative detection method. The results showed that the positive rate of various malignant tumor patients was obvious. Higher than the healthy control group and non-cancer disease group (P<0.005), the total positive rate for malignant tumors was 67.85%, and the specificity was 85.23%. The detection of HPPA in urine before and after surgery, radiotherapy, or chemotherapy found that after effective treatment, especially after surgery, the positive rate of HPPA detection in urine was significantly reduced, which was significantly different from that before treatment (P<0.005). At the same time, the urine HPPA test of patients with tumor progression, recurrence, and metastasis found that the positive application was significantly higher than those in remission, relapse-free, and metastasis. Statistical analysis also showed significant differences (P<0.05-0.005). Therefore, the detection of HPPA in urine can not only be used as a marker of tumor metabolism abnormalities for tumor screening and self-examination, but also as a condition monitoring, efficacy determination, monitoring of relapse or an indicator of prognosis.